文献速递神经肿瘤

阻断MIR155HG/miR-155轴抑制胶质瘤间质转化

Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma.
PubMed 文献 · Neuro Oncol · 2017-01-01

研究分析两个胶质瘤基因表达数据集,发现MIR155HG升高与胶质瘤分级、间质转化和不良预后相关;体外和体内实验显示用小干扰RNA降低MIR155HG可抑制细胞增殖、迁移、侵袭和原位胶质瘤生长;高通量筛选鉴定出NSC141562为MIR155HG/miR-155轴的小分子抑制剂,可能成为抗胶质瘤候选药物。

要点

  • MIR155HG升高与胶质瘤分级、间质转化和不良预后相关。
  • 小干扰RNA降低MIR155HG可抑制胶质瘤细胞增殖、迁移、侵袭和原位生长。
  • NSC141562为MIR155HG/miR-155轴的小分子抑制剂,可能成为抗胶质瘤候选药物。

核心结论

  • MIR155HG/miR-155轴在促进胶质瘤进展中起关键作用,并可作为胶质母细胞瘤患者生存的预后因素。
  • 高通量筛选提示MIR155HG/miR-155轴抑制剂NSC141562可能是有用的抗胶质瘤候选药物。

研究设计与样本

  • 利用两个不同的胶质瘤基因表达数据集分析MIR155HG/miR-155轴表达及其与胶质瘤分级和患者生存的相关性。
  • 通过一系列体外和体内实验阐明生物学意义。
  • 进行高通量筛选小分子以鉴定MIR155HG/miR-155轴的潜在抑制剂。

主要发现

  • MIR155HG升高与胶质瘤分级、间质转化和不良预后相关。
  • 用小干扰RNA降低MIR155HG通过抑制其衍生物miR-155-5p和miR-155-3p的生成,抑制细胞增殖、迁移、侵袭和原位胶质瘤生长。
  • 生物信息学和荧光素酶报告实验显示,原钙黏蛋白9和原钙黏蛋白7分别是miR-155-5p和miR-155-3p的直接靶点,二者通过抑制Wnt/β-catenin通路发挥肿瘤抑制作用。
  • 鉴定出NSC141562为MIR155HG/miR-155轴的有效小分子抑制剂。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MIR155 host gene (MIR155HG) is a long noncoding RNA that has been considered as the primary micro (mi)RNA of miR-155. MIR155HG plays an essential role in hematopoiesis, inflammation, and tumorigenesis. Our study investigated the clinical significance, biological function, mechanisms, and small-molecule inhibitors of the MIR155HG/miR-155 axis in glioma. METHODS: We analyzed the expression of the MIR155HG/miR-155 axis and the correlation with glioma grade and patient survival using 2 different glioma gene expression datasets. Biological significance was elucidated through a series of in vitro and in vivo experiments. Furthermore, we conducted a high-throughput screening for small molecules to identify a potential inhibitor of the MIR155HG/miR-155 axis. RESULTS: Increased MIR155HG was associated with glioma grade, mesenchymal transition, and poor prognosis. Functionally, MIR155HG reduction by small interfering RNA inhibited cell proliferation, migration, invasion, and orthotopic glioma growth by repressing the generation of its derivatives miR-155-5p and miR-155-3p. Bioinformatics and luciferase reporter assays revealed that protocadherin 9 and protocadherin 7, which act as tumor suppressors by inhibiting the Wnt/β-catenin pathway, were direct targets of miR-155-5p and miR-155-3p, respectively. Finally, we identified NSC141562 as a potent small-molecule inhibitor of the MIR155HG/miR-155 axis. CONCLUSIONS: Our results demonstrate that the MIR155HG/miR-155 axis plays a critical role in facilitating glioma progression and serves as a prognostic factor for patient survival in glioblastoma. High-throughput screening indicated that the MIR155HG/miR-155 axis inhibitor NSC141562 may be a useful candidate anti-glioma drug.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Wu X, Wang Y, Yu T, et al. Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma. Neuro Oncol. 2017. PMID: 28371892. doi:10.1093/neuonc/nox017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。